William C Knowler1, Jill P Crandall2. 1. National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA. knowler@nih.gov. 2. Department of Medicine and Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: There have been many randomized clinical trials testing lifestyle and drug interventions to prevent the development of type 2 diabetes in nondiabetic adults at high risk of the disease. We review the major trials using pharmacologic interventions with the primary outcome of preventing diabetes. The trials are grouped according to the main mechanism by which the drugs were thought to have the potential for preventing diabetes. RECENT FINDINGS: Drugs in several different classes have been effective in reducing the incidence of diabetes, but evidence for other long-term benefits, such as avoidance of complications and reducing mortality rates, is very limited. Both drugs and lifestyle interventions are effective in preventing and delaying the onset of type 2 diabetes in high-risk adults. The choices of what drugs to use and when during the development of type 2 diabetes to introduce them are not clear.
PURPOSE OF REVIEW: There have been many randomized clinical trials testing lifestyle and drug interventions to prevent the development of type 2 diabetes in nondiabetic adults at high risk of the disease. We review the major trials using pharmacologic interventions with the primary outcome of preventing diabetes. The trials are grouped according to the main mechanism by which the drugs were thought to have the potential for preventing diabetes. RECENT FINDINGS: Drugs in several different classes have been effective in reducing the incidence of diabetes, but evidence for other long-term benefits, such as avoidance of complications and reducing mortality rates, is very limited. Both drugs and lifestyle interventions are effective in preventing and delaying the onset of type 2 diabetes in high-risk adults. The choices of what drugs to use and when during the development of type 2 diabetes to introduce them are not clear.
Entities:
Keywords:
Pharmacologic prevention; Randomized clinical trials; Type 2 diabetes
Authors: J David Spence; Catherine M Viscoli; Silvio E Inzucchi; Jennifer Dearborn-Tomazos; Gary A Ford; Mark Gorman; Karen L Furie; Anne M Lovejoy; Lawrence H Young; Walter N Kernan Journal: JAMA Neurol Date: 2019-05-01 Impact factor: 18.302
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: David M Nathan; Peter H Bennett; Jill P Crandall; Sharon L Edelstein; Ronald B Goldberg; Steven E Kahn; William C Knowler; Kieren J Mather; Sunder Mudaliar; Trevor J Orchard; Marinella Temprosa; Neil H White Journal: Diabetologia Date: 2019-07-04 Impact factor: 10.122
Authors: Carel W le Roux; Arne Astrup; Ken Fujioka; Frank Greenway; David C W Lau; Luc Van Gaal; Rafael Violante Ortiz; John P H Wilding; Trine V Skjøth; Linda Shapiro Manning; Xavier Pi-Sunyer Journal: Lancet Date: 2017-02-23 Impact factor: 79.321
Authors: Robert E Ratner; Costas A Christophi; Boyd E Metzger; Dana Dabelea; Peter H Bennett; Xavier Pi-Sunyer; Sarah Fowler; Steven E Kahn Journal: J Clin Endocrinol Metab Date: 2008-09-30 Impact factor: 5.958
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Kevin McCarthy; Eamon Laird; Aisling M O'Halloran; Cathal Walsh; Martin Healy; Annette L Fitzpatrick; James B Walsh; Belinda Hernández; Padraic Fallon; Anne M Molloy; Rose Anne Kenny Journal: EClinicalMedicine Date: 2022-09-17